We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+18.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$29.7M
Cap. Flow
+$9.23M
Cap. Flow %
6.1%
Top 10 Hldgs %
42.62%
Holding
71
New
15
Increased
21
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.74M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.78M
3
GILD icon
Gilead Sciences
GILD
+$3.06M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.72M
5
MRK icon
Merck
MRK
+$2.59M

Top Sells

Rank Stock Value
1
TECH icon
Bio-Techne
TECH
+$4.35M
2
CPHD
Cepheid Inc
CPHD
+$4.07M
3
AZN icon
AstraZeneca
AZN
+$2.85M
4
BIIB icon
Biogen
BIIB
+$2.01M
5
MTD icon
Mettler-Toledo International
MTD
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Miscellaneous 14.74%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$1.75M 1.16%
50,000
-8,567
-15% -$552K
LOXO
27
DELISTED
Loxo Oncology, Inc
LOXO
$1.71M 1.13%
+60,000
New +$1.61M
AZN icon
28
AstraZeneca
AZN
$255B
$1.67M 1.1%
24,550
-43,450
-64% -$2.85M
NSTG
29
DELISTED
NanoString Technologies, Inc.
NSTG
$1.5M 0.99%
102,200
– –
PCRX icon
30
Pacira BioSciences
PCRX
$1.03B
$1.47M 0.97%
19,110
-1,890
-9% -$107K
ZGNX
31
DELISTED
Zogenix, Inc.
ZGNX
$1.41M 0.93%
95,700
+30,000
+46% +$403K
RXDX
32
DELISTED
Ignyta, Inc.
RXDX
$1.34M 0.89%
+100,000
New +$1.21M
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.33M 0.88%
17,000
+9,850
+138% +$570K
XNCR icon
34
Xencor
XNCR
$2.15B
$1.32M 0.87%
+90,000
New +$1.21M
DRNA
35
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.19M 0.78%
+100,000
New +$1.14M
MCRB icon
36
Seres Therapeutics
MCRB
$49.7M
$1.16M 0.77%
+1,650
New +$1.08M
PRTK
37
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.14M 0.75%
+60,000
New +$1.15M
ACHN
38
DELISTED
Achillion Pharmaceuticals
ACHN
$1.08M 0.71%
100,000
-6,104
-6% -$55.5K
BIB icon
39
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
$1.07M 0.7%
14,919
-17,798
-54% -$1.19M
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.52B
$1.03M 0.68%
+100,000
New +$994K
UTHR icon
41
United Therapeutics
UTHR
$22.6B
$1.02M 0.67%
6,514
+943
+17% +$137K
MACK
42
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$968K 0.64%
15,570
+7,689
+98% +$541K
MDCO
43
DELISTED
Medicines Co
MDCO
$934K 0.62%
+25,000
New +$945K
MGNX icon
44
MacroGenics
MGNX
$260M
$929K 0.61%
+30,000
New +$911K
VCEL icon
45
Vericel Corp
VCEL
$2.11B
$857K 0.57%
332,157
– –
NVAX icon
46
CALL
Novavax
NVAX
$1.49B
$839K 0.55%
5,000
– –
NVAX icon
47
PUT
Novavax
NVAX
$1.49B
$839K 0.55%
5,000
– –
KPTI icon
48
Karyopharm Therapeutics
KPTI
$44M
$795K 0.53%
4,000
+3,017
+307% +$653K
LAB icon
49
Standard BioTools
LAB
$256M
$757K 0.5%
70,000
+55,000
+367% +$540K
AVDL
50
DELISTED
Avadel Pharmaceuticals
AVDL
$693K 0.46%
56,788
– –
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2015 Portfolio in Review

As of Q4 2015, Opus Point Partners Management held 71 positions worth $151M, down 16% from $181M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management deployed $9.23M of net new capital in Q4 2015, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was Loxo Oncology, Inc: 60,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $2.85M trimmed.

  • Opus Point Partners Management's largest Q4 2015 buy was Loxo Oncology, Inc: 60,000 shares worth $1.71M.
  • Opus Point Partners Management added most to Amgen in Q4 2015, an estimated $4.74M increase.
  • Opus Point Partners Management's biggest Q4 2015 reduction was AstraZeneca, cutting an estimated $2.85M.
  • Opus Point Partners Management fully exited Bio-Techne in Q4 2015, selling an estimated $4.35M.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $151M portfolio in Q4 2015.
  • Opus Point Partners Management opened 15 new positions and closed 14 in Q4 2015.
  • Opus Point Partners Management's portfolio value fell 16% quarter-over-quarter to $151M.

Based on Opus Point Partners Management's 13F filing for Q4 2015, filed 16 Feb 2016.